



# MAYNE PHARMA ANNOUNCES US LAUNCH OF TWO NEW PRODUCTS - DILTIAZEM ER & DORYX® MPC 60 MG

15 February 2023, Adelaide, Australia: Mayne Pharma Group Limited (ASX: MYX) is pleased to announce the US launch of Diltiazem extended-release (ER) capsules and DORYX® MPC 60 mg tablets.

Diltiazem ER capsules are the generic alternative to [Reference Listed Drug (RLD)] CARDIZEM®, a calcium channel blocker used to treat high blood pressure, angina, and certain heart arrhythmias. The Diltiazem ER capsules market is valued at US\$51 million for the 12 months ended November 2022, according to IQVIA, a leading healthcare data and analytics provider.

DORYX® MPC (doxycycline hyclate delayed-release tablets), a tetracycline-class antimicrobial is indicated as adjunctive therapy for severe acne and is already available as a 120 mg dosage strength from Mayne Pharma. This new DORYX® MPC dosage strength will allow Mayne Pharma to target a wider section of the oral tetracycline market, which according to IQVIA has an annual value of more than US\$470m.

Mayne Pharma's CEO Mr Shawn O'Brien said: "The launch of these two new products in the US is an important step for us as we build our portfolio and execute on our commitment to providing patients with high-quality medicines."

Mayne Pharma has more than 60 retail generics and 11 branded products available in the United States.

### For further information contact:

Australia:

Craig Haskins

+61 421 029 843

[ir@maynepharma.com](mailto:ir@maynepharma.com)

US:

Lisa M. Wilson

+917 543 9932

[ir@maynepharma.com](mailto:ir@maynepharma.com)

Authorised for release to the ASX by the Chair

CARDIZEM® is a registered trademark of Bausch Health Ireland Limited.

DORYX® is a registered trademark of Mayne Pharma.

### About Mayne Pharma

Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercialising novel and generic pharmaceuticals, offering patients better, safe and more accessible medicines. Mayne Pharma also provides contract development and manufacturing services to clients worldwide. Mayne Pharma has a 40-year track record of innovation and success in developing new oral drug delivery systems. These technologies have been successfully commercialised in numerous products that continue to be marketed around the world. To learn more about Mayne Pharma, please visit [maynepharma.com](http://maynepharma.com).

### Mayne Pharma Group Limited

ABN 76 115 832 963

[maynepharma.com](http://maynepharma.com)

1538 Main North Road, Salisbury South, SA 5106 Australia